EUVIMEDEUVIMED entdecken
Crossref

NELBI score: a new clinical calculator of thirty-day mortality following systemic anticancer therapy in breast cancer patients near the end of life

Tuğba Önder, Cengiz Karaçin

Breast Cancer · 2025

DOI: 10.1007/s12282-025-01676-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Breast Cancer, 2025. Verfasst von Tuğba Önder und 1 weiteren Autor:innen. Beteiligte Einrichtung: Health Sciences University, Dr Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital, Ankara, Turkey. ondertugba111@gmail.com. Hauptthemen laut MEDLINE: Breast Neoplasms, Palliative Care. Die Arbeit nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS AND OBJECTIVES: Appropriately timed cessation of systemic anticancer treatments is an important part of a patient's quality of life (QoL). We aimed to determine the right time to discontinue systemic anticancer therapy (SACT) and switch to the best supportive care for patients with advanced breast cancer (BC) who are nearing the end of life. METHODS: We identified 200 BC patients who died within 30 days after palliative SACT. Laboratory parameters and Eastern Cooperative Oncology Group (ECOG) performance status (PS) were recorded when the patients received their last SACT and at the time of their penultimate treatment. The (Neutrophil-ECOG-LDH-Bilirubin) 'NELBI' score, created on the basis of the optimum cut-off points of ECOG PS, neutrophil count, bilirubin level, and lactate dehydrogenase (LDH) level, which can predict mortality within 30 days after SACT, was scored between 0 and 4. Patients were stratified on the basis of the NELBI score. RESULTS: A total of 4164 patients receiving palliative treatment for advanced BC were examined. A total of 4.8% of patients died within 30 days after SACT. The percentage of patients who died within 30 days after SACT among all deceased patients was 19.4%. The median time from the last systemic treatment to death was 19.5 ± 7.85 (95% CI 18.06-20.26) days, and the median time from the penultimate treatment to death was 43.0 ± 24.65 (95% CI 46.81-53.85) days. A total of 21.3%, 58.0%, 70.7%, and 88.9% of patients with NELBI scores of 0, 1, 2, and 3-4, respectively, died within 30 days after SACT. Compared with a NELBI score of 0, a NELBI score of 1 (OR = 5.095; 95% CI 2.654- 9.784; p < 0.001), a NELBI score of 2 (OR = 8.911; 95% CI 4.299-18.474; p < 0.001), and a NELBI score of 3-4 (OR = 29.500; 95% CI 6.135- 141.847; p < 0.001) was associated with significantly greater 30-day mortality. The AUC of the NELBI scoring for 30-day mortality prediction after SACT was 0.713. CONCLUSIONS: The 'NELBI' scoring system has the potential to significantly improve patient care by guiding the appropriate discontinuation of SACTs in patients with BC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsPalliative CareHumansFemaleMiddle AgedAgedQuality of LifeBilirubinAdultL-Lactate DehydrogenaseNeutrophilsAged, 80 and overRetrospective StudiesPrognosis

Stichwörter der Autor:innen

30-day mortalityBest supportive careBreast cancerEnd of life

Substanzen

BilirubinL-Lactate Dehydrogenase

Autor:innen und Institutionen

  • Health Sciences University, Dr Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital, Ankara, Turkey. ondertugba111@gmail.com.
  • Health Sciences University, Dr Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital, Ankara, Turkey.

Zitieren

APA

Önder, T., & Karaçin, C. (2025). NELBI score: a new clinical calculator of thirty-day mortality following systemic anticancer therapy in breast cancer patients near the end of life. Breast Cancer. https://doi.org/10.1007/s12282-025-01676-9

Vancouver

Önder T, Karaçin C. NELBI score: a new clinical calculator of thirty-day mortality following systemic anticancer therapy in breast cancer patients near the end of life. Breast Cancer. 2025. doi:10.1007/s12282-025-01676-9

BibTeX
@article{nder2025,
  author = {Önder, Tuğba and Karaçin, Cengiz},
  title = {NELBI score: a new clinical calculator of thirty-day mortality following systemic anticancer therapy in breast cancer patients near the end of life},
  journal = {Breast Cancer},
  year = {2025},
  doi = {10.1007/s12282-025-01676-9}
}
Kostenlos starten →